RxSight Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $121.1M-13.5% YoYTTM through 30 Jun 2026
Net Income -$46.9MTTM through 30 Jun 2026
Free Cash Flow -$27.2MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 76.1% |
| EBITDA Margin | -42.6% |
| Operating Margin | -57.7% |
| Net Margin | -38.8% |
Returns
-17.4%ROE
-15.3%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio10.20x
Net Debt-$217.9Mnet cash position
Cash & Equivalents$13.4M
Quality Metrics
Altman Z-Score-0.69
Piotroski F-Score2 / 9
FCF Margin-22.4%
Rule of 40-8.2
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $134.5M
Diluted EPS-$1.14TTMFY2025: $-0.95
Dividend
No dividend
Capital Allocation
R&D Spend$36.7M
Capex Intensity3.7%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Light Adjustable Lens (LAL) | $27M | 0.0% | View detailsLAL procedures are expected to remain the primary driver of recurring revenue, supported by commercial initiatives to deepen practice integration. |
| Light Delivery Device (LDD) | $24M | -74.5% | View detailsLDD placements are expected to be lower year-over-year in 2026, consistent with slower adoption trends among practices. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.